clinical trial · NCT06716424
A Study to Investigate Safety and Efficacy of iGlarLixi in Adult Patients With Type 2 Diabetes Mellitus
Type 2 DiabetesiGlarLixi (insulin glargine/lixisenatide)
brief summary
This is an intervention, phase IV, single-arm study to assess the safety and efficacy of iGlarLixi in adult patients with Type 2 diabetes.
started
Jan 6, 2025
primary completion
Jun 26, 2026
completion
Jun 26, 2026
last updated
Apr 8, 2026
detailed description
The study duration will be up to 27 weeks, with a treatment duration approximately 24 weeks.
official title
Multicentre Phase IV Single Arm Clinical Trial to Evaluate the Safety and Efficacy of a Fixed Ratio Combination of Insulin Glargine and Lixisenatide in Adult Patients With Type 2 Diabetes Who Are Sub Optimally Controlled on Oral Anti-hyperglycemic Drugs and/or Basal Insulin/GLP-1 RA
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol